Exclusive interviews with leading policymakers that convey the true policy message that impacts markets.
Reporting on key macro data at the time of release.
Real-time insight on key fixed income and fx markets.
- Emerging MarketsEmerging Markets
Real-time insight of emerging markets in CEMEA, Asia and LatAm region
- Political RiskPolitical Risk
Intelligence on key political and geopolitical events around the world.
- About Us
Moderna has released a statement following trials of its vaccine on the two most prevalent variants of COVID-19, those first identified in the UK and South Africa.
- With regard to the B.1.1.7 UK variant, Moderna said that 'The study showed no significant impact on neutralizing titers against the B.1.1.7 variant relative to prior variants.'
- Against the B.1.531 South Africa variant 'A six-fold reduction in neutralizing titers was observed with the B.1.351 variant relative to prior variants. Despite this reduction, neutralizing titer levels with B.1.351 remain above levels that are expected to be protective.'
- 'The two-dose regimen of the Moderna COVID-19 Vaccine at the 100 microgram dose is expected to be protective against emerging strains detected to date.'
- Moderna CEO Stephane Bancel: 'Out of an abundance of caution and leveraging the flexibility of our mRNA platform, we are advancing an emerging variant booster candidate against the variant first identified in the Republic of South Africa into the clinic to determine if it will be more effective to boost titers against this and potentially future variants.'